SCHEMBL4853047

SCHEMBL4853047

Cc1ccc(NC(=N)c2ccccc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.61
RAB9A P51151 7/20 0.61
HPGD P15428 2/20 0.61
MAPT P10636 2/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
GLA P06280 1/20 0.50
CACNA1B Q00975 1/20 0.50
APBA1 Q02410 1/20 0.50
PTGS2 P35354 1/20 0.49
ALDH1A1 P00352 2/20 0.47
LMNA P02545 1/20 0.47
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
TDP1 Q9NUW8 1/20 0.45
CES2 O00748 1/20 0.45
CES1 P23141 1/20 0.45
EGFR P00533 1/20 0.45
MMP1 P03956 1/20 0.45
MMP2 P08253 1/20 0.45
MMP9 P14780 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2154879 0.92 NPC1 (0.52) NPC1RAB9AHPGDMAPTSMN1; SMN2
SCHEMBL21424948 0.90 NPC1 (0.57) NPC1RAB9AHPGDMAPTSMN1; SMN2
SCHEMBL393417 0.85 ALDH1A1 (0.48) NPC1RAB9ASMN1; SMN2ALDH1A1MEN1
Hydrochloric Acid SCHEMBL9773792 0.83 ALDH1A1 (0.46) NPC1RAB9ASMN1; SMN2ALDH1A1MEN1
SCHEMBL457388 0.83 ALDH1A1 (0.46) NPC1RAB9ASMN1; SMN2ALDH1A1MEN1
SCHEMBL23332259 0.83 NPC1 (0.52) NPC1RAB9AHPGDMAPTSMN1; SMN2
SCHEMBL8423709 0.82 LMNA (0.51) NPC1RAB9AHPGDMAPTSMN1; SMN2
SCHEMBL19937963 0.82 GAA (0.53) NPC1RAB9AHPGDMAPTALDH1A1
SCHEMBL4861779 0.81 CA1 (0.53) NPC1RAB9AHPGDSMN1; SMN2ALDH1A1
SCHEMBL14223445 0.81 NPC1 (0.48) NPC1RAB9AHPGDMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109796372-A A method of preparing polysubstituted alkenyl amidine 中国科学院化学研究所 2019-05-24 CN disclosed
US-7365069-B2 Pyrimidone derivatives BEXEL PHARMACEUTICALS INC. (US) 2008-04-29 US disclosed
US-7365069-B2 Pyrimidone derivatives BEXEL PHARMACEUTICALS INC. (US) 2008-04-29 US disclosed
US-7365069-B2 Pyrimidone derivatives BEXEL PHARMACEUTICALS INC. (US) 2008-04-29 US disclosed
US-20040259891-A1 Novel pyrimidon derivatives ORCHID CHEMICAL & PHARMACEUTICALS LIMITED (IN) 2004-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259891-A1 Novel pyrimidon derivatives TYMS, TPMT, TYMP NPC1 1563/4885RAB9A 2079/4885HPGD 1077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.